About 14.5 million U.S. cancer survivors are alive today, but aging population and increasing obesity threaten progress.
Researchers have developed a new integrated approach to identify the genetic drivers of cancer, uncovering eight genes necessary for cell proliferation in breast cancer.
Epidermal growth factor receptor mutations found in ctDNA in the plasma of patients with advanced non-small cell lung cancer correlates well with the EGFR mutations from patient-matched tumor tissue DNA.
Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.
New research suggests that an antidepressant medication, repurposed, could target a novel molecular pathway that causes an aggressive form of medulloblastoma.
Researchers have identified a gene that contributes to the development of several childhood cancers, research that could lead to new strategies for targeting certain childhood cancers at a molecular level.
In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers report that they have identified a possible new drug target for treating the disease.
A new molecular analysis tool accurately detected the level of an important target for immunotherapy in early stage breast cancers.
Researchers have developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma.
Research has shown that a mutated form of T. gondii may help galvanize the human immune system to fight cancer.
The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.
A research team has created a new, self-assembling nanoparticle that can increase the effectiveness of magnetic resonance imaging (MRI) cancer detection.
Changes in how follicular lymphoma is managed have led to substantial improvement in prognosis and over all survival for patients with the disease.
Scientists have shown that DNA origami can be used for the targeted delivery of cancer drugs to tumor cells in mice.
Researchers from The Cancer Genome Atlas Research Network have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer.
An international team of scientists have discovered a faulty process in certain bladder cancers that could point to new ways to treat patients with an aggressive form of the disease.
Studying mouth cancer in mice, researchers have found a way to predict the aggressiveness of similar tumors in people, an early step toward a diagnostic test that could guide treatment.
Researchers have found that as antihistamines do their job, they also interfere with the function of myeloid-derived suppressor cells—a type of cell known to hinder the body's ability to combat tumors.
Cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment, according to a new study.
Up to 40% of patients with lung cancer do not respond to a targeted therapy designed to block tumor growth. Now, scientists have discovered why that intrinsic resistance occurs.
New findings from a large phase I study of patients with advanced melanoma show that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.
Researchers have identified a therapeutic target for treating the most common form of eye cancer in adults.
A new type of therapy, human papillomavirus (HPV)-targeted adoptive T-cell therapy, shows promise in treating some women with advanced cervical cancer, but side effects were often severe.
Scientists from the Florida campus of The Scripps Research Institute have found new targets for potential intervention in breast cancer.
Genetically modifying immune cells might effectively treat multiple myeloma, according to a new study.
By targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, according to new research.
Resistance to a combination of HER2-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors, which are the target of a number of drugs under development.
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck may benefit from treatment with the investigational drug dacomitinib.
The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer.
The important role of microRNAs in regulating neuroblastoma development has been unveiled by new research.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|